Myriad Genetics Inc
MYGN· Nasdaq
MYGNMyriad Genetics Inc
Filed Aug 6, 2025 · 10-Q · 37 days after period end · 0000899923-25-000086
| Metric | Q2 2025 | Q2 2024 | Q2 2023 | Q2 2022 |
|---|---|---|---|---|
| Revenue | $213.10M | $211.50M | $183.50M | $179.30M |
| Net Income | -$330.50M | -$36.70M | -$116.10M | -$14.10M |
| EPS Diluted | -$3.57 | -$0.41 | -$1.42 | -$0.18 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Myriad Genetics Inc · CIK 899923 · Engraved from SEC EDGAR
ended Jun 30, 2025 · filed Aug 6, 2025 · 37 d after period end
